Interview with Ajit Kamath, Chairman & Managing Director, Arch Pharmalabs
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Address: 541-A, Arch House, Marol Maroshi Road,
Andheri (E), Mumbai – 400 059, India
Tel: 91-22-33089200/33089400
Web: http://www.archpharmalabs.com/index.asp
We are a pharmaceutical company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. We have evolved our business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to our offerings, which has significant potential for the growth of our business.
Lipid Lowering Agent
Calcium Channel Blocker
Anti Platelet Agent
Anti hypertensive
Anti anginal
Anti Asthmatic
Anti Histamine
Anti Diabetic
Anti Protozoal
Anti fungal
Oncology
Anti emetic
Proton pump inhibitor
Expectorant
Decongestant
Anti Depressant
Anti Convulsant
Psychostimulant
Hypnotic
Anti parkinsonian
Anti Retroviral
Anti gout
Analgesic
We have evolved to include Contract Research and Manufacturing Services as our growing business vertical. We have developed capabilities to provide a wide range of CRAMS starting from route selection / process development / optimization, analytical development, stability studies, safety studies, scale-up to technology transfer / clinical-trial manufacturing to commercial manufacturing to suit US / EU regulatory requirements. We can cost-effectively manage several complex reactions at various scales of operation, ranging from a few grams to several tonnes. For instance, we, using a proprietary bio-catalytic/ enzymatic technology availed by us, have developed innovative route for the manufacturing of key advanced intermediates.
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Sir Dr. Huz, CEO and trustee of the Wockhardt Foundation and executive director of Wockhardt, discusses the role the Foundation plays in low- and middle-income areas across India, and how integrating simple…
The secretary-general of the Indian Drug Manufacturers Association (IDMA) gives his insight into the current state of the Indian pharma industry, the IDMA’s role in raising the quality of Indian-made…
The Indian joint secretary for commerce and industry, interviewed at CPhI Worldwide 2014 in Paris, discusses India’s place in the global pharmaceutical landscape, and emphasizes the country’s contribution to the…
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
PAREXEL has had a long-term commitment to India. Could you give us a brief overview of your activities in the country? PAREXEL offers clinical development services throughout India. In 2004,…
TCS Life Sciences and Healthcare vertical was created within the Tata Group 10 years ago. Can you explain to the readers, how such a diversified group such as Tata decided…
Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain…
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Over the years, multinational corporations (MNCs) have increasingly been penetrating the Indian pharmaceutical markets. How have you observed this trend throughout your career? Based on India’s macro-economic growth of around…
See our Cookie Privacy Policy Here
